TOP Israeli Oncologist – Melanoma and Skin Cancer Institute
Position: Chairman of the Melanoma and Immunooncology Institute Ella Lamelbaum
Hospital: Sheba Medical Center, Israel
Prof. Schechter is in the Forbes list of the best Israeli doctors
Qualified Medical Consultation Online, Second Opinion on Melanoma Convectional and Innovative Treatment
Qualified Medical Consultation
Early and Metastatic stages of: Melanoma of soft tissue, Melanoma retina, Uveal melanoma, (Eye melanoma), Mucosal melanoma, Superficial, Nodular, Acrolenti-Ginous, Amelanotic (pigmentless) Melanoma and others.
Send Your Medical Files Book Consultation Now
Treatment Provided:
- Immunotherapy Intravenous and Intrathecal
- Targeted therapy
- Ajuvant therapy
- Radiation therapy
- TIL therapy for melanoma
- FMT therapy (Fecal Microbiome Transplant)
Education:
- 1969-1976 – School of Medicine, Hebrew University, Jerusalem
- 1982-1986 – Specialization in Oncology, Beilinson Hospital, Rabin Medical Center, Petah Tikva
Dr. Jacob Schechter Experience:
Since 2014 till present Prof. Schechter is a Chairman of the Ella Lamelbaum Institute for Melanoma and Immunooncology
Institute Overview:
- Under Prof. Schechter’s guidance, the Melanoma and Immunooncology Institute at Sheba Academic Medical Center offers a unique approach to melanoma treatment.
- The institute conducts studies aimed at developing future treatment prospects for melanoma.
- Collaborations with the Advanced Technologies Center and the Department of Plastic Surgery and Surgical Oncology facilitate patient observation, innovative surgical methods, and diverse treatment approaches.
Cutting-Edge Therapy:
- The institute offers the most promising experimental therapy for melanoma.
- Israeli Melanoma Institute is among the few institutions worldwide, alongside the National Institute of Health (NIH) in the United States, known for such advanced treatment.
Academic Activity:
- Dr. Schechter is a Chairman of the Department of Oncology, Sackler School of Medicine, Tel Aviv University
- Member of the Israeli Society of Oncology and Clinical Radiotherapy
- Head of the Israeli Melanoma Society Forum
Prof. Schechter has carried out about 100 epidemiological studies published in leading medical journals.
Some of dr. Schechter publications:
- Pembrolizumab versus ipilimumab in advanced melanoma. Epub 2019 Jul 22.PMID: 31345627 Clinical Trial
- Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science. 2021 Feb
- Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915). Clin Oncol. 2023 Jan, Epub 2022 Sep 26.
